2005 in cancer

FDA · US: 43 records / 24 drugsHealth Canada · CA: 7 records / 6 drugsEMA · EU: 2 records / 2 drugs

• Dec 27, 2005Lenalidomide FDA · US original application approved Mantle Cell Lymphoma. • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomibopenfda
• Dec 27, 2005Lenalidomide FDA · US original application approved Chronic Lymphocytic Leukemia. Limitations of Use: • REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of…openfda
• Dec 27, 2005Lenalidomide FDA · US original application approved Follicular Lymphoma. • Previously treated follicular lymphoma (FL), in combination with a rituximab productopenfda
• Dec 27, 2005Lenalidomide FDA · US original application approved Myelodysplastic Syndrome. • Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without…openfda
• Dec 27, 2005Lenalidomide FDA · US original application approved Marginal Zone Lymphoma. • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab productopenfda
• Dec 27, 2005Lenalidomide FDA · US original application approved Multiple MyelomaMultiple myeloma (MM), in combination with dexamethasoneopenfda
• Dec 1, 2005Sorafenib Tosylate FDA · US original application approved Hepatocellular CarcinomaNEXAVAR is a kinase inhibitor indicated for the treatment of • Unresectable hepatocellular carcinomaopenfda
• Dec 1, 2005Sorafenib FDA · US original application approved Renal Cell CarcinomaAdvanced renal cell carcinomaopenfda
• Dec 1, 2005Sorafenib FDA · US original application approved Differentiated Thyroid Gland CarcinomaLocally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatmentopenfda
• Dec 1, 2005Sorafenib FDA · US original application approved Hepatocellular CarcinomaNEXAVAR is a kinase inhibitor indicated for the treatment of • Unresectable hepatocellular carcinomaopenfda
• Dec 1, 2005Sorafenib Tosylate FDA · US original application approved Renal Cell CarcinomaAdvanced renal cell carcinomaopenfda
• Dec 1, 2005Sorafenib Tosylate FDA · US original application approved Differentiated Thyroid Gland CarcinomaLocally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatmentopenfda
• Oct 29, 2005Tamoxifen FDA · US original application approved Malignant Breast NeoplasmFor adjuvant treatment of adult patients with early stage estrogen receptor- positive breast canceropenfda
• Oct 29, 2005Tamoxifen FDA · US original application approved Malignant Breast NeoplasmTo reduce the incidence of breast cancer in adult women at high riskopenfda
• Oct 29, 2005Tamoxifen FDA · US original application approved Malignant Breast NeoplasmFor treatment of adult patients with estrogen receptor-positive metastatic breast canceropenfda
• Jan 7, 2005Paclitaxel FDA · US original application approved Malignant Breast NeoplasmMetastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy…openfda
• Jan 7, 2005Paclitaxel FDA · US original application approved Pancreatic AdenocarcinomaMetastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.openfda
• Jan 7, 2005Paclitaxel FDA · US original application approved Lung Non-Small Cell CarcinomaLocally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates…openfda
• Dec 27, 2005Lenalidomide FDA · US original application approved cancer not stated in this record. • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)openfda
• Oct 29, 2005Tamoxifen FDA · US original application approved cancer not stated in this recordTo reduce risk of invasive breast cancer following breast surgery and radiation in adult women with ductal carcinoma in situ (DCIS)openfda
• Oct 28, 2005Nelarabine FDA · US original application approved cancer not stated in this recordARRANON is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients…openfda
• Jun 3, 2005Metformin FDA · US original application approved cancer not stated in this recordMetformin Hydrochloride Extended-Release Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes…openfda
• Dec 28, 2005Letrozole FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2005-12-28 (see label)openfda
• Dec 15, 2005Triptorelin Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as TRELSTAR (DIN 02240000) under ATC L02AE04 TRIPTORELIN. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Dec 15, 2005Triptorelin Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as TRELSTAR (DIN 02243856) under ATC L02AE04 TRIPTORELIN. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Dec 2, 2005Interferon Beta-1a Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as AVONEX (DIN 02269201) under ATC L03AB07 INTERFERON BETA-1A. Indications are not published in the Drug Product Database — see the Health…health-canada-dpd
• Nov 2, 2005Bevacizumab Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as AVASTIN (DIN 02270994) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Oct 20, 2005Imatinib Mesylate FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2005-10-20 (see label)openfda
• Oct 20, 2005Imatinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2005-10-20 (see label)openfda
• Oct 5, 2005Exemestane FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2005-10-05 (see label)openfda
• Sep 29, 2005Bevacizumab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2005-09-29 (see label)openfda
• Sep 19, 2005Erlotinib EMA · EU centralised approved cancer not stated in this recordNon-small cell lung cancer (NSCLC) Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell…ema
• Sep 16, 2005Anastrozole FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2005-09-16 (see label)openfda
• Sep 15, 2005Pegfilgrastim FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2005-09-15 (see label)openfda
• Aug 15, 2005Leuprolide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as ELIGARD (DIN 02268892) under ATC L02AE02 LEUPRORELIN. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Aug 11, 2005Meloxicam FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2005-08-11 (see label)openfda
• Jul 29, 2005Celecoxib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2005-07-29 (see label)openfda
• Jul 27, 2005Ibritumomab Tiuxetan FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2005-07-27 (see label)openfda
• Jun 15, 2005Capecitabine FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2005-06-15 (see label)openfda
• May 13, 2005Peginterferon Alfa-2a FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2005-05-13 (see label)openfda
• Apr 5, 2005Imatinib Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as GLEEVEC (DIN 02253275) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Mar 25, 2005Bortezomib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2005-03-25 (see label)openfda
• Mar 15, 2005Temozolomide FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2005-03-15 (see label)openfda
• Mar 14, 2005Imatinib Mesylate FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2005-03-14 (see label)openfda
• Mar 14, 2005Imatinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2005-03-14 (see label)openfda
• Mar 11, 2005Sirolimus FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2005-03-11 (see label)openfda
• Mar 11, 2005Sirolimus FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2005-03-11 (see label)openfda
• Mar 2, 2005Epirubicin FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2005-03-02 (see label)openfda
• Feb 25, 2005Peginterferon Alfa-2a FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2005-02-25 (see label)openfda
• Feb 1, 2005Bortezomib Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as VELCADE (DIN 02262452) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Jan 28, 2005Doxorubicin FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2005-01-28 (see label)openfda
• Jan 12, 2005Bevacizumab EMA · EU centralised approved cancer not stated in this recordBevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or…ema

RegulatoryAll 2005 records with filters →

Studies

3,180

Interventional

2,888

Phase III

587

Industry-led

795

With posted results

700

Countries with sites

82

Published source: clinicaltrials · first_posted_date as posted